Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380
about
Predictive biomarkers in precision medicine and drug development against lung cancerRAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Simultaneous determination and validation of oncrasin-266 and its metabolites by HPLC-MS/MS: Application to a pharmacokinetic study
P2860
Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380
@ast
Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380
@en
Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380
@nl
type
label
Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380
@ast
Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380
@en
Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380
@nl
prefLabel
Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380
@ast
Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380
@en
Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380
@nl
P2093
P2860
P1476
Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380
@en
P2093
Bingliang Fang
Jack A Roth
Mengru Cao
Qing H Meng
Shuhong Wu
Stephen G Swisher
P2860
P304
P356
10.1016/J.BMC.2014.08.006
P407
P577
2014-08-14T00:00:00Z